Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"Antibody-drug conjugate (ADC)"”.
-
Synthesis and biological evaluation of auristatin-F recombinant antibody-drug conjugates for cancer therapy
… as a contribution to the emerging field of antibody-drug conjugate (ADC) therapeutics, in which novel ADCs were generated and biologically evaluated for therapeutic potential and specificity towards cancer cells. SNAP-tag site-directed conjugation was employed in order to overcome the …
-
Targeting the actin cytoskeleton in HER2+ metastatic cancer cells using a macrolide toxin
… B (MycB), as a potential warhead for a novel antibody drug conjugate (ADC) to target highly metastatic HER2+ breast and ovarian cancers. We found that MycB treatment of HER2+ breast (SKBR3, MDA-MB-453) and ovarian (SKOV3) cancer cells led to loss of viability (IC50 values ≤ 64 nM). Sub-lethal …
-
A NOVEL, RAS-INDEPENDENT ROLE FOR NF1 IN MICROTUBULE DYNAMICS AND DAMAGE REPAIR DICTATES SENSITIVITY TO T-DM1 IN HER2 POSITIVE BREAST CANCER.
… cancer cells to T-DM1, the first approved Antibody-drug conjugate (ADC) in breast cancer, through a novel, RAS-independent function on microtubular dynamics and repair. NF1 exhibits all biochemical properties of a bona fide MAP and specifically enhances intratubular repair. These results …
-
The Mechanism of cGAMP Induced Antitumor Effect and Its Application in Treating Cancer and Antibody Generation
… toxicity. Chapter Four describes developing an antibody-drug conjugate (ADC) that links a STING agonist to antibodies targeting EGFR, prevalent in many cancers. This STING ADC activates various immune cells and promotes macrophage polarization within tumors. Chapter Five utilizes cGAMP as an …
-
NF1 AS A REGULATOR OF CYTOSKELETON DYNAMICS AND BIOMARKER FOR DECISION-MAKING IN HER2-POSITIVE BREAST CANCER
… cells demonstrated exquisite sensitivity to the antibody-drug conjugate (ADC) trastuzumab emtansine (T-DM1). This hypersensitivity was specific to the mertansine MT-targeting component (DM1) since it was i) replicated by the naked payload but not the antibody alone; ii) absent with other ADCs …
-
Targeting the Tumor Stroma Using a Monoclonal Antibody Platform Technology
… the discovery and validation of a monoclonal antibody that selectively binds to FAP. The lead antibody, B12, was identified from a naïve murine single-chain variable fragment antibody phage display library screened against recombinant human FAP. The heavy and light chains of B12 were cloned …
-
Design of smart linkers and their applications in controlled-release drug delivery systems
Antibody drug conjugates (ADC) represents an interesting strategy in tumour targeted therapy . The approach is based on the combination of the high affinity of an antibody towards its antigen and the high cytotoxicity of a drug, leading to a selective therapuetic agent with improved efficacy and …
-
Generation and therapeutic evaluation of recombinant immunotherapeutics on CD64+ monocytic cell lines and polarized ex vivo differentiated human macrophages
… population. Methods: The CD64-targeting antibody fragment (H22(scFv)) was used to generate; 1) a recombinant immunotoxin (rIT) through genetic fusion with the enzymatic domain of Pseudomonas aeruginosa exotoxin A (ETA`), or 2) a SNAP-tag fusion protein (FP) to allow chemical coupling of …